CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190

Ulrika Petersson, Annika; Andreas Bauer, Udo; Martin Birch, Alan; John Butlin, Roger; Clive Green; Gunnar Barlind, Jonas; Ragnar Hovland; Petra Johannesson; Magnus Johansson, Jan; Andrew Leach; Tobias Noeske, Alexander

CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190

Ulrika Petersson, Annika (Inventor), Andreas Bauer, Udo (Inventor), Martin Birch, Alan (Inventor), John Butlin, Roger (Inventor), Clive Green (Inventor), Gunnar Barlind, Jonas (Inventor), Ragnar Hovland (Inventor), Petra Johannesson (Inventor), Magnus Johansson, Jan (Inventor), Andrew Leach (Inventor), Tobias Noeske, Alexander (Inventor)

Pharmacy

Research output: Patent

Abstract

DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is =O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or -O-; Y2 is -(CH 2) r- wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or -O-; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

Original language	English
Patent number	WO2009081195
IPC	C07D 403/ 10 A I
Priority date	20/12/07
Publication status	Published - 2 Jul 2009

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009081195

Cite this

@misc{3d73ad10b6fb457b9b59f8dadb31e1ab,

title = "CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190",

abstract = "DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is =O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or -O-; Y2 is -(CH 2) r- wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or -O-; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.",

author = "{Petersson, Annika}, Ulrika and {Bauer, Udo}, Andreas and {Birch, Alan}, Martin and {Butlin, Roger}, John and Clive Green and {Barlind, Jonas}, Gunnar and Ragnar Hovland and Petra Johannesson and {Johansson, Jan}, Magnus and Andrew Leach and {Noeske, Alexander}, Tobias",

year = "2009",

month = jul,

day = "2",

language = "English",

type = "Patent",

note = "WO2009081195; C07D 403/ 10 A I",

}

TY - PAT

T1 - CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190

AU - Petersson, Annika, Ulrika

AU - Bauer, Udo, Andreas

AU - Birch, Alan, Martin

AU - Butlin, Roger, John

AU - Green, Clive

AU - Barlind, Jonas, Gunnar

AU - Hovland, Ragnar

AU - Johannesson, Petra

AU - Johansson, Jan, Magnus

AU - Leach, Andrew

AU - Noeske, Alexander, Tobias

PY - 2009/7/2

Y1 - 2009/7/2

N2 - DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is =O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or -O-; Y2 is -(CH 2) r- wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or -O-; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

AB - DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is =O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or -O-; Y2 is -(CH 2) r- wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or -O-; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

M3 - Patent

M1 - WO2009081195

ER -

CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190

Abstract

Access to Document

Fingerprint

Cite this